Regencell Bioscience Holdings Ltd Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2025
Net Income -$3.6MTTM through 30 Jun 2025
Free Cash Flow -$3.3MTTM through 30 Jun 2025
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
-73.7%ROE
-62.3%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio7.39x
Net Debt-$4.9Mnet cash position
Cash & Equivalents$2.4M
Quality Metrics
Altman Z-Score2,057.13
Piotroski F-Score2 / 9
Multi-Year Trend
Diluted EPS-$0.72TTMFY2025: $-0.01
Dividend
No dividend
Capital Allocation
R&D Spend$948.3K
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Traditional Chinese Medicine (TCM) Research and Development | $0 | 0.0% | View detailsThe company continues to focus on the research and development of TCM formulae candidates for neurocognitive disorders such as ADHD and ASD. Future outlook depends entirely on clinical trial progress and regulatory approvals. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.